The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of S-1 plus leucovorin (a new 1-week treatment regimen followed by a 1-week rest period) in patients with untreated metastatic colorectal cancer in Japan and China.
Tadamichi Denda
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Jin Li
No relevant relationships to disclose
Ruihua Xu
No relevant relationships to disclose
Jianming Xu
No relevant relationships to disclose
Koji Ikejiri
No relevant relationships to disclose
Lin Shen
No relevant relationships to disclose
Yasushi Toh
Honoraria - Taiho Pharmaceutical
Ken Shimada
No relevant relationships to disclose
Takeshi Kato
Honoraria - Taiho Pharmaceutical; Taiho Pharmaceutical
Hideo Baba
Honoraria - Taiho Pharmaceutical